All In Biotech

NDA 019011 · Azurity

Golytely

Polyethylene Glycol 3350, Potassium Chloride, Sodium Bicarbonate, Sodium Chloride, Sodium Sulfate Anhydrous · Oral · Osmotic Laxative

Last checked: Nov 20, 2026Latest source record: May 14, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Jul 13, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

127

31 Phase 3, 9 recruiting

FAERS reports

1,328

748 serious, 83 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 8, 2026.

PEG-3350 and Electrolytes for Oral Solution is indicated for bowel cleansing prior to colonoscopy and barium enema X-ray examination in adults. PEG-3350 and Electrolytes for Oral Solution is a combination of PEG 3350, an osmotic laxative, and electrolytes indicated for cleansing of the colon in preparation for colonoscopy and barium enema X-ray examination in adults ( 1 )

Mechanism: The primary mode of action is thought to be through the osmotic effect of polyethylene glycol 3350 which causes water to be retained in the colon and produces a watery stool.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 13, 1984 Original approval · Type 4 - New Combination
2 products under this application
  • GOLYTELY · POLYETHYLENE GLYCOL 3350 236GM/BOT; POTASSIUM CHLORIDE 2.97GM/BOT; SODIUM BICARBONATE 6.74GM/BOT; SODIUM CHLORIDE 5.86GM/BOT; SODIUM SULFATE ANHYDROUS 22.74GM/BOT · FOR SOLUTION, ORAL · Prescription · TE AA
  • GOLYTELY · POLYETHYLENE GLYCOL 3350 227.1GM/PACKET; POTASSIUM CHLORIDE 2.82GM/PACKET; SODIUM BICARBONATE 6.36GM/PACKET; SODIUM CHLORIDE 5.53GM/PACKET; SODIUM SULFATE ANHYDROUS 21.5GM/PACKET · FOR SOLUTION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Polyethylene Glycol 3350" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting214
  • nausea171
  • abdominal pain98
  • abdominal distension92
  • diarrhoea79
  • fatigue78
  • drug ineffective76
  • headache72
  • constipation71
  • pain67
  • wrong technique in product usage process62
  • chronic kidney disease57

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
200516
200613
20076
20087
200920
201013
201127
201228
201336
201438
201567
2016116
2017115
2018118
2019134
2020107
202175
202299
202369
202479
202586
202653

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Golytely (PEG3350/Sod Sulf,Bicarb,Cl/KCl)

2024 spending

$205K

Beneficiaries

7,584

8,171 claims

Per beneficiary

$27

$0.01 per unit

View as table
YearSpending
2020$500,642
2021$330,220
2022$452,020
2023$261,461
2024$204,739

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 95 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.